Pradeep Thanigaimani

1.2k total citations · 1 hit paper
11 papers, 669 citations indexed

About

Pradeep Thanigaimani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Pradeep Thanigaimani has authored 11 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Pradeep Thanigaimani's work include Cancer Immunotherapy and Biomarkers (8 papers), Prostate Cancer Treatment and Research (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Pradeep Thanigaimani is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Prostate Cancer Treatment and Research (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Pradeep Thanigaimani collaborates with scholars based in United States, South Korea and Canada. Pradeep Thanigaimani's co-authors include Sanatan Saraf, Jonathan D. Cheng, Alain P. Algazi, Roger B. Cohen, Christophe Le Tourneau, Samuel Ejadi, Caroline Even, Emilie M.J. van Brummelen, Aaron R. Hansen and Se‐Hoon Lee and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Pradeep Thanigaimani

11 papers receiving 664 citations

Hit Papers

Safety and Antitumor Activity of Pembrolizumab in Patient... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
    2017 300 citations Chiun Hsu, Se‐Hoon Lee et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pradeep Thanigaimani United States 7 503 200 177 175 129 11 669
Chi‐Chung Tong China 13 271 0.5× 230 1.1× 286 1.6× 136 0.8× 96 0.7× 31 590
Yan Mao China 6 336 0.7× 138 0.7× 162 0.9× 140 0.8× 29 0.2× 19 555
Yungpo Bernard Su United States 7 255 0.5× 157 0.8× 174 1.0× 263 1.5× 85 0.7× 11 549
J. Cheng United States 12 331 0.7× 97 0.5× 83 0.5× 148 0.8× 17 0.1× 27 504
Bhumsuk Keam South Korea 9 312 0.6× 48 0.2× 28 0.2× 134 0.8× 247 1.9× 17 568
Kartik Viswanathan United States 11 186 0.4× 145 0.7× 24 0.1× 80 0.5× 51 0.4× 28 423
Hari A. Deshpande United States 10 136 0.3× 57 0.3× 53 0.3× 90 0.5× 80 0.6× 46 363
Gabriel Calzada United States 9 144 0.3× 210 1.1× 207 1.2× 59 0.3× 76 0.6× 13 402
Kelly K. Curtis United States 12 130 0.3× 110 0.6× 61 0.3× 146 0.8× 14 0.1× 25 375
C. Blajman Argentina 9 446 0.9× 180 0.9× 307 1.7× 425 2.4× 8 0.1× 15 759

Countries citing papers authored by Pradeep Thanigaimani

Since Specialization
Citations

This map shows the geographic impact of Pradeep Thanigaimani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pradeep Thanigaimani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pradeep Thanigaimani more than expected).

Fields of papers citing papers by Pradeep Thanigaimani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pradeep Thanigaimani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pradeep Thanigaimani. The network helps show where Pradeep Thanigaimani may publish in the future.

Co-authorship network of co-authors of Pradeep Thanigaimani

This figure shows the co-authorship network connecting the top 25 collaborators of Pradeep Thanigaimani. A scholar is included among the top collaborators of Pradeep Thanigaimani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pradeep Thanigaimani. Pradeep Thanigaimani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Kelly, William Kevin, Sandy Srinivas, Joseph Maly, et al.. (2025). Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations
3.
Stein, Mark N., Jingsong Zhang, William Kevin Kelly, et al.. (2023). Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). 154–154. 15 indexed citations
4.
Kelly, William Kevin, Arif Hussain, Biren Saraiya, et al.. (2023). A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). TPS284–TPS284. 1 indexed citations
5.
Kelly, William Kevin, et al.. (2022). A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS5105–TPS5105. 6 indexed citations
6.
Mehnert, Janice M., Andréa Varga, Marcia S. Brose, et al.. (2019). Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer. BMC Cancer. 19(1). 196–196. 148 indexed citations
7.
Cohen, Roger B., Jean‐Pierre Delord, Toshihiko Doi, et al.. (2018). Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. American Journal of Clinical Oncology. 41(11). 1083–1088. 145 indexed citations
8.
Hsu, Chiun, Se‐Hoon Lee, Samuel Ejadi, et al.. (2017). Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. Journal of Clinical Oncology. 35(36). 4050–4056. 300 indexed citations breakdown →
9.
Mehnert, Janice M., Andréa Varga, Marcia S. Brose, et al.. (2016). Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study.. Journal of Clinical Oncology. 34(15_suppl). 6091–6091. 32 indexed citations
10.
Hsu, Chih‐Hung, Seung‐Hoon Lee, Samuel Ejadi, et al.. (2015). 315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Annals of Oncology. 26. ix93–ix93. 13 indexed citations
11.
Hsu, Chih‐Hung, Samuel Ejadi, Caroline Even, et al.. (2015). 2801 Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a hase 1b study. European Journal of Cancer. 51. S558–S558. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chi‐Chung Tong Breakdown of academic impact, for papers by Yan Mao Breakdown of academic impact, for papers by Yungpo Bernard Su Breakdown of academic impact, for papers by J. Cheng Breakdown of academic impact, for papers by Bhumsuk Keam Breakdown of academic impact, for papers by Kartik Viswanathan Breakdown of academic impact, for papers by Hari A. Deshpande Breakdown of academic impact, for papers by Gabriel Calzada Breakdown of academic impact, for papers by Kelly K. Curtis Breakdown of academic impact, for papers by C. Blajman
Rankless by CCL
2026